Wiley
Wiley.com
Print this page Share
E-book

Heart Failure: Pharmacologic Management

ISBN: 978-1-4051-7253-0
304 pages
April 2008, Wiley-Blackwell
Heart Failure: Pharmacologic Management (1405172533) cover image
Now there is an up-to-date guide for optimizing pharmacologic therapy in treating patients with heart failure. Reflecting current practice at leading medical centers, Heart Failure: Pharmacologic Management provides both the biologic and pathologic underpinnings of each pharmacologic agent in current use. It also supplies detailed discussions of the clinical investigations that support current understanding of the risks and benefits associated with the use of these drugs. Thorough references make the book useful to the novice as well as the experienced clinician.

Initial chapters focus on agents that are considered standard care:


  • diuretics
  • ACE inhibitors
  • angiotensin receptor antagonists
  • aldosterone antagonists
  • beta-blockers

The discussion moves to agents currently under investigation:


  • Vasopressin antagonists
  • erythropoietin

Next, the authors consider some controversial drugs:


  • inotropic agents
  • antiarrhythmic drugs
  • anticoagulants

An insightful examination of pharmacogenetics considers:


  • how studies of the genetic profile of patients helps determine which patient populations are most likely to respond to a given class of drugs
  • the potential use of pharmacogenetics to tailor a pharmacologic regimen for maximum benefit and minimum risk

Multidrug pharmacy for heart failure therapy

An extremely helpful concluding chapter provides a roadmap of drugs with which to approach the patient with heart failure, along with an overview of the skills you need to use it most effectively. This straightforward, step-by-step algorithm will save you countless hours of research and help you make your prescribing decisions with confidence.

See More
Contributors.

Introduction.

1. Diuretics in congestive heart failure (Alicia Ross, Ray E. Hershberger and David H. Ellison).

2. Use of digoxin in the treatment of heart failure (Deborah DeEugenio and Paul J. Mather).

3. Renin-angiotensin system and angiotensin converting enzyme inhibitors in chronic heart failure (Rimvida Obeleniene and Marrick Kukin).

4. Angiotensin receptor blockers in the treatment of hart failure (Anita Deswal and Douglas L. Mann).

5. Beta blockers (Peter F. Robinson and Michael R. Bristow).

6. Aldosterone antagonism in the pharmacological management of chronic heart failure (Biykem Bozkurt).

7. Inotropic therapy in clinical practice (Sharon Rubin and Theresa Pondok).

8. Antiarrhythmic therapy in heart failure (Igino Contrafatto and Leslie A. Saxon).

9. Treating the hypercoagulable state of heart failure: modifying the risk of arterial and venous thromboembolism (Geno J. Meril and Hoard H. Weitz).

10. Vasodilator and nitrates (Abdul Al-Hesayen and John D. Parker).

11. Natriuretic peptides fro the treatment of heart failure (Jonathan D. Sackner-Bernstein, Hal Skopicki and Keith D. Aaronson).

12. Immune modulatory therapies in heart failure: using myocarditis to gain mechanistic insights (Grace Chan, Koichi Fuse, Mei Sun, Bill Ayach and Peter P. Liu).

13. The role of vasopressin and vasopressin antagonists in heart failure (Olaf Hedrich, Maervin A. Konstam and James Eric Udelson).

14. Role of erythropoietin in the correction of anemia in patients with heart failure (Revecca P. Streeter and Donna M. Mancini).

15. Endothelin antagonism cardiovascular disease (Srinivas Murali).

16. Pharmacogenetics (Richard Sheppard and Dennis M. McNamara).

17. Management of diastolic dysfunction (Arthur M. Feldman and Bonita Fakner).

18. Multidrug pharmacy for treatment of heart failure: an algorithm for the clinician (Mariell Jessup).

Index.

See More
An informative guide to optimizing the use of pharmacologic therapy for patients with heart failure

  • Includes the biologic and pathologic underpinning for the use of each pharmacologic agent currently recommended
  • Discusses agents that are considered standard care, and those still under investigation or controversial
  • Covers the emerging field of pharmacogenetics and the genetic profile of patients
See More

Related Titles

Back to Top